Markers of Bone Status in Diabetes Mellitus (Type 1 and Type 2)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

197 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-03-31

Study Completion Date

2015-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objective To collate the bone status in type 1 and type 2 diabetics using biochemical markers and bone scans.

Methods:

This is a multicenter trial involving the University Hospitals of three major danish cities: Aalborg, Aarhus and Odense. The trial is of cross-sectional design and consists of examinations including:

* Blood samples to analyze bone markers, glycemic state, kidney function and sex-hormones.
* 24 hour urine sample to analyze bone markers and kidney function.
* Bone scans including dual energy x-ray absorptiometry (DXA) and high resolution peripheral quantitative computed tomography (HRpQCT) to evaluate Bone Mineral Density, t-score and bone structure.

Participants:

100 type 1 diabetics and 100 type 2 diabetics recruited from outpatient clinics at Aalborg, Aarhus and Odense, general practitioners and flyers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of Glycemic Control on Skeletal Outcomes in Adults With Type 1 Diabetes

NCT06351176

Diabetes Mellitus, Type 1 Bone Health Bone Loss +2 more

ENROLLING_BY_INVITATION

Microarchitecture, Bone Strength and Fracture Risk in Type 2 Diabetes

NCT02551315

Type 2 Diabetes Mellitus Bone Fractures

COMPLETED

Bone Structure in Patients With Adult Onset Growth Hormone Deficiency Assessed Using High Resolution Peripheral Quantitative Computed Tomography

NCT02218710

Adult Onset Growth Hormone Deficiency

COMPLETED

Bone Health and Microbiome in Persons With Type 1 Diabetes

NCT04784975

Type1diabetes

COMPLETED

Bone Properties Following Exercise Induced Changes in Insulin Sensitivity in People With Type 2 Diabetes

NCT06668090

Diabetes Mellitus, Type 2 Insulin Resistance Bone Diseases, Metabolic +4 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Diabetes Mellitus and Osteoporosis are common conditions. Patients with Diabetes Mellitus are known to have more fractures than their non-diabetic counterparts. However bone mineral density (BMD) which is the most commonly used measure of fracture risk seems to be insensitive in diabetes, thus BMD is lowered in type 1 diabetes but not enough to explain an almost seven fold in fracture risk. BMD is increased in type 2 diabetes although they still have an increased fracture risk.

The investigators investigate this paradox in diabetes by assessing type 1 and type 2 diabetes patients bone status by blood- and urine samples (assessing markers of bone- and glycemic state) and two types of bone scans comprising of DXA and HRpQCT scan.

The diabetes mellitus patients are recruited from outpatients clinics in the three study sites (Aalborg, Aarhus and Odense) as well as general practitioners and by flyers and adds.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus Osteoporosis Osteopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diabetes Mellitus type 1

n=100

No interventions assigned to this group

Diabetes Mellitus type 2

n=100

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 1 or type 2 diabetes.
* Age ≥ 50 years.
* Unaltered treatment of diabetes during the previous six months (no changes in drugs, but an increase or decrease in dose is accepted) and HbA1c is stable with a level of ± 1 in the same period.
* HbA1c level≥ 7 % through the previous six months.
* BMI between 19 og 35.

* Either treatment with metformin, sulfonylureas, dipeptidyl peptidase IV (DPP IV) inhibitors or glucagon-like peptide 1 (GLP-1) analogs.
* Treatment with insulin and insulin in the combination with metformin, sulfonylureas, DPP IV inhibitors or GLP-1 analogs.

Exclusion Criteria

* HbA1C \> 10%
* Pregnancy.
* Metal implanted at both ankles and wrists.
* Patients treated with: Antiresorptive (incl. hormone replacement therapy) or bone anabolic treatment, glucocorticoids, lithium and anticonvulsives.
* Patients with a bone disease other than osteoporosis.
* Vertebral fracture visible by vertebral fracture assessment (VFA).
* Patients with renal disease defined by estimated glomerular filtration rate(eGFR) \< 50.
* Other medical disease in unstable phase (fx. cancer, hyperthyroidism).
* Heart failure; New York Heart Association (NYHA) class IV.
* Patients which the investigator does not believe is fit to participate in the study

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No